New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?

Over the last few decades, improved knowledge of oncogenic activation mechanisms of HER2 protein has led to the development of HER2 targeted therapies that are currently commonly used in HER2-positive advanced breast cancer, such as trastuzumab, lapatinib, pertuzumab, and ado-trastuzumab emtansine....

Descripción completa

Detalles Bibliográficos
Autores principales: Mezni, Essia, Vicier, Cécile, Guerin, Mathilde, Sabatier, Renaud, Bertucci, François, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352740/
https://www.ncbi.nlm.nih.gov/pubmed/32545895
http://dx.doi.org/10.3390/cancers12061573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352740/
https://www.ncbi.nlm.nih.gov/pubmed/32545895
http://dx.doi.org/10.3390/cancers12061573

Ejemplares similares